Business Description
Anebulo Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US0345691036
Description
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.87 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 81.09 | |||||
| 9-Day RSI | 70.14 | |||||
| 14-Day RSI | 64.45 | |||||
| 6-1 Month Momentum % | 30.96 | |||||
| 12-1 Month Momentum % | 29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.72 | |||||
| Quick Ratio | 6.72 | |||||
| Cash Ratio | 6.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -97.37 | |||||
| ROA % | -88.11 | |||||
| ROIC % | -1556.5 | |||||
| ROCE % | -98.26 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 11.8 | |||||
| Price-to-Tangible-Book | 12 | |||||
| EV-to-EBIT | -6.6 | |||||
| EV-to-EBITDA | -6.6 | |||||
| EV-to-FCF | -7.29 | |||||
| Price-to-Net-Current-Asset-Value | 13.71 | |||||
| Price-to-Net-Cash | 13.71 | |||||
| Earnings Yield (Greenblatt) % | -15.15 | |||||
| FCF Yield % | -12.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Anebulo Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.39 | ||
| Beta | 0 | ||
| Volatility % | 30.34 | ||
| 14-Day RSI | 64.45 | ||
| 14-Day ATR (€) | 0.087302 | ||
| 20-Day SMA (€) | 2.61 | ||
| 12-1 Month Momentum % | 29 | ||
| 52-Week Range (€) | 1.71 - 2.88 | ||
| Shares Outstanding (Mil) | 25.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Anebulo Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Anebulo Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Anebulo Pharmaceuticals Inc Frequently Asked Questions
What is Anebulo Pharmaceuticals Inc(FRA:214)'s stock price today?
The current price of FRA:214 is €2.88. The 52 week high of FRA:214 is €2.88 and 52 week low is €1.71.
When is next earnings date of Anebulo Pharmaceuticals Inc(FRA:214)?
The next earnings date of Anebulo Pharmaceuticals Inc(FRA:214) is 2024-05-10 Est..
Does Anebulo Pharmaceuticals Inc(FRA:214) pay dividends? If so, how much?
Anebulo Pharmaceuticals Inc(FRA:214) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers